Oral therapy for riboflavin transporter deficiency: What is the regimen of choice?Show others and affiliations
2019 (English)In: Parkinsonism & Related Disorders, ISSN 1353-8020, E-ISSN 1873-5126, Vol. 61, p. 245-247Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
Elsevier, 2019. Vol. 61, p. 245-247
Keywords [en]
Ataxia, Recessive, Riboflavin transporter deficiency, Treatment, Brown-Vialetto-Van Laere syndrome-2, BVVLS2, Pharmacokinetics, SLC52A2, Adult
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-74642DOI: 10.1016/j.parkreldis.2018.10.017ISI: 000468719900047PubMedID: 30343981Scopus ID: 2-s2.0-85065409488OAI: oai:DiVA.org:oru-74642DiVA, id: diva2:1322023
Note
Funding Agencies:
Sickle University Hospital Research Foundation
Swedish Parkinson Foundation (Parkinsonfonden) in Sweden
Swedish National Health Services (ALF-YF) in Sweden
MultiPark a strategic research environment at Lund University in Sweden
Swedish Parkinson Academy in Sweden
Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research in Sweden
National Human Genome Research Institute
National Heart, Lung and Blood Institute 1U54HG006493
2019-06-102019-06-102019-06-10Bibliographically approved